Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors

F. Fazio, L. Lionetto, G. Molinaro, H. O. Bertrand, F. Acher, R. T. Ngomba, S. Notartomaso, M. Curini, O. Rosati, P. Scarselli, R. Di Marco, G. Battaglia, V. Bruno, M. Simmaco, J. P. Pin, F. Nicoletti, Cyril Goudet

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Cinnabarinic acid is an endogenous metabolite of the kynurenine pathway that meets the structural requirements to interact with glutamate receptors. We found that cinnabarinic acid acts as a partial agonist of type 4 metabotropic glutamate (mGlu4) receptors, with no activity at other mGlu receptor subtypes. We also tested the activity of cinnabarinic acid on native mGlu4 receptors by examining 1) the inhibition of cAMP formation in cultured cerebellar granule cells; 2) protection against excitotoxic neuronal death in mixed cultures of cortical cells; and 3) protection against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine toxicity in mice after local infusion into the external globus pallidus. In all these models, cinnabarinic acid behaved similarly to conventional mGlu4 receptor agonists, and, at least in cultured neurons, the action of low concentrations of cinnabarinic acid was largely attenuated by genetic deletion of mGlu4 receptors. However, high concentrations of cinnabarinic acid were still active in the absence of mGlu4 receptors, suggesting that the compound may have off-target effects. Mutagenesis and molecular modeling experiments showed that cinnabarinic acid acts as an orthosteric agonist interacting with residues of the glutamate binding pocket of mGlu4. Accordingly, cinnabarinic acid did not activate truncated mGlu4 receptors lacking the N-terminal Venus-flytrap domain, as opposed to the mGlu4 receptor enhancer, N-phenyl-7-(hydroxyimino)cyclopropa[b-]chromen-1a-carboxamide (PHCCC). Finally, we could detect endogenous cinnabarinic acid in brain tissue and peripheral organs by high-performance liquid chromatography-tandem mass spectrometry analysis. Levels increased substantially during inflammation induced by lipopolysaccharide. We conclude that cinnabarinic acid is a novel endogenous orthosteric agonist of mGlu4 receptors endowed with neuroprotective activity.

Original languageEnglish (US)
Pages (from-to)643-656
Number of pages14
JournalMolecular Pharmacology
Volume81
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Kynurenine
Droseraceae
cinnabarinic acid
metabotropic glutamate receptor 4
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Globus Pallidus
Glutamate Receptors
Tandem Mass Spectrometry
Mutagenesis
Lipopolysaccharides
Glutamic Acid
Cell Culture Techniques
High Pressure Liquid Chromatography
Inflammation

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Medicine
  • Pharmacology

Cite this

Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. / Fazio, F.; Lionetto, L.; Molinaro, G.; Bertrand, H. O.; Acher, F.; Ngomba, R. T.; Notartomaso, S.; Curini, M.; Rosati, O.; Scarselli, P.; Di Marco, R.; Battaglia, G.; Bruno, V.; Simmaco, M.; Pin, J. P.; Nicoletti, F.; Goudet, Cyril.

In: Molecular Pharmacology, Vol. 81, No. 5, 01.05.2012, p. 643-656.

Research output: Contribution to journalArticle

Fazio, F, Lionetto, L, Molinaro, G, Bertrand, HO, Acher, F, Ngomba, RT, Notartomaso, S, Curini, M, Rosati, O, Scarselli, P, Di Marco, R, Battaglia, G, Bruno, V, Simmaco, M, Pin, JP, Nicoletti, F & Goudet, C 2012, 'Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors', Molecular Pharmacology, vol. 81, no. 5, pp. 643-656. https://doi.org/10.1124/mol.111.074765
Fazio, F. ; Lionetto, L. ; Molinaro, G. ; Bertrand, H. O. ; Acher, F. ; Ngomba, R. T. ; Notartomaso, S. ; Curini, M. ; Rosati, O. ; Scarselli, P. ; Di Marco, R. ; Battaglia, G. ; Bruno, V. ; Simmaco, M. ; Pin, J. P. ; Nicoletti, F. ; Goudet, Cyril. / Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. In: Molecular Pharmacology. 2012 ; Vol. 81, No. 5. pp. 643-656.
@article{93550e9669634df3ac4c8e9eb4c79f46,
title = "Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors",
abstract = "Cinnabarinic acid is an endogenous metabolite of the kynurenine pathway that meets the structural requirements to interact with glutamate receptors. We found that cinnabarinic acid acts as a partial agonist of type 4 metabotropic glutamate (mGlu4) receptors, with no activity at other mGlu receptor subtypes. We also tested the activity of cinnabarinic acid on native mGlu4 receptors by examining 1) the inhibition of cAMP formation in cultured cerebellar granule cells; 2) protection against excitotoxic neuronal death in mixed cultures of cortical cells; and 3) protection against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine toxicity in mice after local infusion into the external globus pallidus. In all these models, cinnabarinic acid behaved similarly to conventional mGlu4 receptor agonists, and, at least in cultured neurons, the action of low concentrations of cinnabarinic acid was largely attenuated by genetic deletion of mGlu4 receptors. However, high concentrations of cinnabarinic acid were still active in the absence of mGlu4 receptors, suggesting that the compound may have off-target effects. Mutagenesis and molecular modeling experiments showed that cinnabarinic acid acts as an orthosteric agonist interacting with residues of the glutamate binding pocket of mGlu4. Accordingly, cinnabarinic acid did not activate truncated mGlu4 receptors lacking the N-terminal Venus-flytrap domain, as opposed to the mGlu4 receptor enhancer, N-phenyl-7-(hydroxyimino)cyclopropa[b-]chromen-1a-carboxamide (PHCCC). Finally, we could detect endogenous cinnabarinic acid in brain tissue and peripheral organs by high-performance liquid chromatography-tandem mass spectrometry analysis. Levels increased substantially during inflammation induced by lipopolysaccharide. We conclude that cinnabarinic acid is a novel endogenous orthosteric agonist of mGlu4 receptors endowed with neuroprotective activity.",
author = "F. Fazio and L. Lionetto and G. Molinaro and Bertrand, {H. O.} and F. Acher and Ngomba, {R. T.} and S. Notartomaso and M. Curini and O. Rosati and P. Scarselli and {Di Marco}, R. and G. Battaglia and V. Bruno and M. Simmaco and Pin, {J. P.} and F. Nicoletti and Cyril Goudet",
year = "2012",
month = "5",
day = "1",
doi = "10.1124/mol.111.074765",
language = "English (US)",
volume = "81",
pages = "643--656",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors

AU - Fazio, F.

AU - Lionetto, L.

AU - Molinaro, G.

AU - Bertrand, H. O.

AU - Acher, F.

AU - Ngomba, R. T.

AU - Notartomaso, S.

AU - Curini, M.

AU - Rosati, O.

AU - Scarselli, P.

AU - Di Marco, R.

AU - Battaglia, G.

AU - Bruno, V.

AU - Simmaco, M.

AU - Pin, J. P.

AU - Nicoletti, F.

AU - Goudet, Cyril

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Cinnabarinic acid is an endogenous metabolite of the kynurenine pathway that meets the structural requirements to interact with glutamate receptors. We found that cinnabarinic acid acts as a partial agonist of type 4 metabotropic glutamate (mGlu4) receptors, with no activity at other mGlu receptor subtypes. We also tested the activity of cinnabarinic acid on native mGlu4 receptors by examining 1) the inhibition of cAMP formation in cultured cerebellar granule cells; 2) protection against excitotoxic neuronal death in mixed cultures of cortical cells; and 3) protection against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine toxicity in mice after local infusion into the external globus pallidus. In all these models, cinnabarinic acid behaved similarly to conventional mGlu4 receptor agonists, and, at least in cultured neurons, the action of low concentrations of cinnabarinic acid was largely attenuated by genetic deletion of mGlu4 receptors. However, high concentrations of cinnabarinic acid were still active in the absence of mGlu4 receptors, suggesting that the compound may have off-target effects. Mutagenesis and molecular modeling experiments showed that cinnabarinic acid acts as an orthosteric agonist interacting with residues of the glutamate binding pocket of mGlu4. Accordingly, cinnabarinic acid did not activate truncated mGlu4 receptors lacking the N-terminal Venus-flytrap domain, as opposed to the mGlu4 receptor enhancer, N-phenyl-7-(hydroxyimino)cyclopropa[b-]chromen-1a-carboxamide (PHCCC). Finally, we could detect endogenous cinnabarinic acid in brain tissue and peripheral organs by high-performance liquid chromatography-tandem mass spectrometry analysis. Levels increased substantially during inflammation induced by lipopolysaccharide. We conclude that cinnabarinic acid is a novel endogenous orthosteric agonist of mGlu4 receptors endowed with neuroprotective activity.

AB - Cinnabarinic acid is an endogenous metabolite of the kynurenine pathway that meets the structural requirements to interact with glutamate receptors. We found that cinnabarinic acid acts as a partial agonist of type 4 metabotropic glutamate (mGlu4) receptors, with no activity at other mGlu receptor subtypes. We also tested the activity of cinnabarinic acid on native mGlu4 receptors by examining 1) the inhibition of cAMP formation in cultured cerebellar granule cells; 2) protection against excitotoxic neuronal death in mixed cultures of cortical cells; and 3) protection against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine toxicity in mice after local infusion into the external globus pallidus. In all these models, cinnabarinic acid behaved similarly to conventional mGlu4 receptor agonists, and, at least in cultured neurons, the action of low concentrations of cinnabarinic acid was largely attenuated by genetic deletion of mGlu4 receptors. However, high concentrations of cinnabarinic acid were still active in the absence of mGlu4 receptors, suggesting that the compound may have off-target effects. Mutagenesis and molecular modeling experiments showed that cinnabarinic acid acts as an orthosteric agonist interacting with residues of the glutamate binding pocket of mGlu4. Accordingly, cinnabarinic acid did not activate truncated mGlu4 receptors lacking the N-terminal Venus-flytrap domain, as opposed to the mGlu4 receptor enhancer, N-phenyl-7-(hydroxyimino)cyclopropa[b-]chromen-1a-carboxamide (PHCCC). Finally, we could detect endogenous cinnabarinic acid in brain tissue and peripheral organs by high-performance liquid chromatography-tandem mass spectrometry analysis. Levels increased substantially during inflammation induced by lipopolysaccharide. We conclude that cinnabarinic acid is a novel endogenous orthosteric agonist of mGlu4 receptors endowed with neuroprotective activity.

UR - http://www.scopus.com/inward/record.url?scp=84859999860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859999860&partnerID=8YFLogxK

U2 - 10.1124/mol.111.074765

DO - 10.1124/mol.111.074765

M3 - Article

C2 - 22311707

AN - SCOPUS:84859999860

VL - 81

SP - 643

EP - 656

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -